Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy.
Seregni E, Maccauro M, Chiesa C, Mariani L, Pascali C, Mazzaferro V, De Braud F, Buzzoni R, Milione M, Lorenzoni A, Bogni A, Coliva A, Lo Vullo S, Bombardieri E. Seregni E, et al. Among authors: maccauro m. Eur J Nucl Med Mol Imaging. 2014 Feb;41(2):223-30. doi: 10.1007/s00259-013-2578-5. Eur J Nucl Med Mol Imaging. 2014. PMID: 24233003 Clinical Trial.
Nuclear medicine imaging of neuroendocrine tumours.
Bombardieri E, Maccauro M, De Deckere E, Savelli G, Chiti A. Bombardieri E, et al. Among authors: maccauro m. Ann Oncol. 2001;12 Suppl 2:S51-61. doi: 10.1093/annonc/12.suppl_2.s51. Ann Oncol. 2001. PMID: 11762353 Free article. Review.
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results.
Chiesa C, Botta F, Di Betta E, Coliva A, Maccauro M, Aliberti G, Bavusi S, Devizzi L, Guidetti A, Seregni E, Gianni AM, Bombardieri E. Chiesa C, et al. Among authors: maccauro m. Cancer Biother Radiopharm. 2007 Feb;22(1):113-20. doi: 10.1089/cbr.2007.302. Cancer Biother Radiopharm. 2007. PMID: 17627419 Clinical Trial.
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin's lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C, Botta F, Coliva A, Maccauro M, Devizzi L, Guidetti A, Carlo-Stella C, Seregni E, Gianni MA, Bombardieri E. Chiesa C, et al. Among authors: maccauro m. Eur J Nucl Med Mol Imaging. 2009 Nov;36(11):1745-57. doi: 10.1007/s00259-009-1141-x. Epub 2009 May 20. Eur J Nucl Med Mol Imaging. 2009. PMID: 19455328 Clinical Trial.
84 results